Form 4: VolitionRx CFO Terig Hughes Reports Changes in Beneficial Ownership

Chief Financial Officer of VolitionRx, Terig Hughes, reports the vesting of restricted stock units and cancellation of unvested units.

Summary

• On August 15, 2024, VolitionRx CFO Terig Hughes reported changes in beneficial ownership of the company's stock.
• These changes involve restricted stock units (RSUs) awarded in September 2023 under the company's 2015 Stock Incentive Plan.
• The award was subject to both performance-based and time-based vesting conditions.
• Certain performance goals were met, resulting in 19,500 RSUs vesting.
• These RSUs are subject to a 3-year time-based vesting schedule, with 6,500 units vesting annually on September 28, 2024, 2025, and 2026.
• Previously, 33,150 RSUs had vested and remain subject to time-based vesting.
• However, 25,350 RSUs did not meet the performance goals and were cancelled on August 15, 2024.
• Following these transactions, Hughes directly owns 350,076 shares of VolitionRx common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While some performance goals were met, leading to RSU vesting, others were not, resulting in cancellation. The CFO's continued stock ownership is a positive sign.

Positives

• The vesting of RSUs indicates that certain corporate performance goals were achieved.
• Hughes' continued direct ownership of 350,076 shares demonstrates ongoing investment in the company.

Negatives

• The cancellation of 25,350 RSUs suggests that some corporate performance goals were not met.

Risks

• Failure to meet future performance goals could impact the vesting of additional RSUs.
• Changes in market conditions could affect the value of Hughes' holdings in VolitionRx.

Future Outlook

The remaining vested RSUs will continue to vest in installments on September 28 of 2025 and 2026.

Industry Context

Changes in beneficial ownership are a routine part of executive compensation and are closely watched by investors for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation in the biotechnology industry, often tied to performance metrics and time-based vesting schedules.
• Companies like Exact Sciences and Guardant Health also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and performance goals associated with these grants vary depending on the company's specific circumstances and strategic objectives.

Stakeholder Impact

• Shareholders may view the vesting of RSUs as a positive sign, indicating that the company is achieving its performance goals.
• Employees may be motivated by the fact that executives are incentivized to improve company performance.
• The cancellation of some RSUs may raise concerns about the company's ability to consistently meet its targets.

Next Steps

• The remaining vested RSUs will vest in installments on September 28, 2025, and September 28, 2026.
• Hughes is required to report any further changes in beneficial ownership to the SEC.

Key Dates